Swedish Orphan Biovitrum AB (publ) - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SWOBY Over the counter 2830 www.sobi.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Swedish Orphan Biovitrum AB (publ)

Sobi to present new clinical and real-world data at EHA 2026 in Stockholm - Jun 11th, 2026 12:35 am
Did Positive Tryngolza Phase 3 Data Just Shift Swedish Orphan Biovitrum's (OM:SOBI) Investment Narrative? - Jun 1st, 2026 11:13 am
Sobi to present new data on pegcetacoplan at ERA 2026 - Jun 1st, 2026 2:19 am
New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia - May 26th, 2026 8:50 am
Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi - May 22nd, 2026 5:00 am
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout - May 21st, 2026 2:54 pm
Bulletin from Sobi's Annual General Meeting (AGM) - May 6th, 2026 4:21 am
Assessing Swedish Orphan Biovitrum’s Valuation After A Period Of Building Share Price Momentum - May 4th, 2026 12:14 pm
Altuviiio (Swedish Orphan Biovitrum) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F - Apr 29th, 2026 9:34 am
Swedish Orphan Biovitrum AB (BIOVF) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and ... - Apr 29th, 2026 1:03 am
Sobi Q1 2026 report: Strong execution and pipeline momentum - Apr 28th, 2026 12:25 am
Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN - Apr 9th, 2026 2:21 pm
EMA Validation Puts SOBI’s Tryngolza And Valuation Gap In Focus - Apr 7th, 2026 3:12 pm
Sobi publishes Annual and Sustainability Report for 2025 - Mar 31st, 2026 5:03 am
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) - Mar 27th, 2026 1:56 am
Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030 - Feb 18th, 2026 12:36 am
Sobi’s Arthrosi Deal Brings Late Stage Gout Asset Into Focus - Feb 12th, 2026 6:14 pm
Sobi to host a Capital Markets Day on 18 February 2026 - Feb 11th, 2026 5:24 am
Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout - Feb 9th, 2026 7:47 am
Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress - Feb 5th, 2026 12:25 am